

Sean Whittaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7646754/publications.pdf>

Version: 2024-02-01

94
papers

11,560
citations

108046

37
h-index

58552

86
g-index

95
all docs

95
docs citations

95
times ranked

5758
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
2	Clinical, histopathological and prognostic features of primary cutaneous acral ⁺ Tâ€cell lymphoma and other dermal ⁺ cutaneous lymphoproliferations: results of an ⁺ EORTC</sup> Cutaneous Lymphoma Group workshop*. <i>British Journal of Dermatology</i> , 2022, 186, 887-897.	1.4	12
3	Flow cytometry for the assessment of blood tumour burden in cutaneous Tâ€cell lymphoma: towards a standardized approach. <i>British Journal of Dermatology</i> , 2022, 187, 21-28.	1.4	9
4	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.4	39
5	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.4	18
6	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
7	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46
8	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21
9	Violaceous facial nodules. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 642-645.	0.6	0
10	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). <i>Hematological Oncology</i> , 2019, 37, 286-288.	0.8	2
11	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. <i>Lancet Oncology</i> , 2019, 20, 1160-1170.	5.1	119
12	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. <i>British Journal of Dermatology</i> , 2019, 180, 496-526.	1.4	111
13	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
14	â€It's a traumatic illness, traumatic to witnessâ€™: a qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 179, 882-888.	1.4	13
15	U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 569-570.	1.4	8
16	Primary cutaneous CD30⁺ anaplastic large-cell lymphoma associated with fingolimod. <i>British Journal of Dermatology</i> , 2018, 179, 1400-1401.	1.4	9
17	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1192-1204.	5.1	398
18	Increased Expression of PLS3 Correlates with Better Outcome in SÃ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 754-757.	0.3	7

#	ARTICLE	IF	CITATIONS
19	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	6.3	444
20	The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 627-633.	0.4	59
21	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/S�azary syndrome " Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
22	Diffuse large B-cell lymphoma developing in erythrodermic cutaneous T-cell lymphoma: a case series. <i>British Journal of Dermatology</i> , 2017, 177, e138-e140.	1.4	4
23	Nonhealing surgical wound due to cutaneous malakoplakia. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 123-125.	0.6	4
24	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.3	16
25	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
26	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. <i>Hematological Oncology</i> , 2017, 35, 77-78.	0.8	2
27	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017, 35, 245-247.	0.8	1
28	PATIENT�REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017, 35, 247-248.	0.8	2
29	Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. <i>Blood</i> , 2017, 130, 817-817.	0.6	15
30	Temozolomide for central nervous system involvement in mycosis fungoides. <i>International Journal of Dermatology</i> , 2016, 55, 751-756.	0.5	11
31	Indolent <scp>CD8</scp>�positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 125-136.	0.7	46
32	Evaluation of Immunophenotypic and Molecular Biomarkers for S�azary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1364-1372.	0.3	78
33	How I treat mycosis fungoides and S�azary syndrome. <i>Blood</i> , 2016, 127, 3142-3153.	0.6	138
34	Global Patterns of Methylation in S�azary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1753-1754.	0.3	8
35	Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 637-643.	0.2	19
36	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. <i>Blood</i> , 2016, 128, 1826-1826.	0.6	6

#	ARTICLE	IF	CITATIONS
37	First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.. Journal of Clinical Oncology, 2016, 34, TPS2591-TPS2591.	0.8	0
38	“We had to change to single beds because I itch in the night”: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2015, 173, 83-92.	1.4	31
39	Aggressive epidermotropic cutaneous CD8 ⁺ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology, 2015, 67, 425-441.	1.6	86
40	“We’re all carrying a burden that we’re not sharing”: a qualitative study of the impact of cutaneous T-cell lymphoma on the family. British Journal of Dermatology, 2015, 172, 1581-1592.	1.4	32
41	Multiple cutaneous, oropharyngeal and pulmonary nodules. British Journal of Dermatology, 2015, 173, 540-543.	1.4	0
42	Whole Exome Sequencing of Flow Purified Tumour Cells Reveals Recurrently Mutated Genes and Pathways in Adult T-Cell Lymphoma/Leukaemia (ATLL). Blood, 2015, 126, 1469-1469.	0.6	1
43	Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker Research, 2014, 2, 16.	2.8	26
44	Erythroderma is not all psoriasis: a case of SÃ©zary syndrome. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 50-51.	0.2	2
45	Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study. Blood, 2014, 124, 4451-4451.	0.6	2
46	A Cutaneous Lymphoma International Consortium “CLIC” study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging. Blood, 2014, 124, 1621-1621.	0.6	2
47	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. European Journal of Cancer, 2013, 49, 2859-2868.	1.3	121
48	Results of a 5-Week Schedule of Modern Total Skin Electron Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 936-941.	0.4	25
49	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2013, 168, 192-200.	1.4	81
50	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. British Journal of Cancer, 2013, 109, 2566-2573.	2.9	35
51	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma		

#	ARTICLE	IF	CITATIONS
55	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. Blood, 2011, 118, 4024-4035.	0.6	365
56	Guidelines for the management of mature Tâ€cell and NKâ€cell neoplasms (excluding cutaneous Tâ€cell) Tj ETQq0 0,0 rgBT /Overlock 1	1.2	103
57	Clinical End Points and Response Criteria in Mycosis Fungoides and SÃ©zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 2011, 29, 2598-2607.	0.8	550
58	A Cutaneous T-Cell Lymphoma EORTC Trials Platform. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S90-S92.	0.2	1
59	EORTC 21012: Phase II Multicentre Study of Caelyxâ„¢ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.. Blood, 2010, 116, 2823-2823.	0.6	1
60	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. Blood, 2010, 116, 4896-4896.	0.6	0
61	Bexarotene therapy for mycosis fungoides and SÃ©zary syndrome. British Journal of Dermatology, 2009, 160, 1299-1307.	1.4	96
62	Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.. Blood, 2009, 114, 3701-3701.	0.6	2
63	Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.. Blood, 2009, 114, 3709-3709.	0.6	13
64	Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. Journal of Clinical Oncology, 2009, 27, 8572-8572.	0.8	10
65	Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.. Blood, 2009, 114, 2683-2683.	0.6	2
66	Folliculotropic mycosis fungoides (stage IIA) progressing to SÃ©zary syndrome: a case report. British Journal of Dermatology, 2008, 159, 1197-9.	1.4	10
67	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood, 2008, 111, 838-845.	0.6	617
68	European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood, 2008, 112, 1600-1609.	0.6	415
69	Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. Blood, 2008, 112, 263-263.	0.6	8
70	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and SÃ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007, 110, 479-484.	0.6	452
71	Revisions to the staging and classification of mycosis fungoides and SÃ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007, 110, 1713-1722.	0.6	1,243
72	Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. British Journal of Dermatology, 2006, 154, 7-20.	1.4	108

#	ARTICLE	IF	CITATIONS
73	Molecular staging of lymph nodes from 60 patients with mycosis fungoides and SÅ©zary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. British Journal of Dermatology, 2006, 155, 756-762.	1.4	46
74	Biological Insights into the Pathogenesis of Cutaneous T-Cell Lymphomas (CTCL). Seminars in Oncology, 2006, 33, 3-6.	0.8	20
75	Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.. Blood, 2006, 108, 2468-2468.	0.6	2
76	International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. Journal of Clinical Oncology, 2006, 24, 3063-3063.	0.8	11
77	Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy. British Journal of Dermatology, 2005, 152, 1346-1348.	1.4	22
78	WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.	0.6	3,529
79	Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology, 2003, 149, 1095-1107.	1.4	220
80	Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. British Journal of Dermatology, 2002, 147, 464-475.	1.4	153
81	Cutaneous lymphoma. , 2001, , 233-251.		0
82	Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood, 2001, 97, 624-630.	0.6	142
83	Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. British Journal of Dermatology, 2001, 144, 735-744.	1.4	133
84	A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. British Journal of Dermatology, 2001, 144, 1010-1015.	1.4	50
85	Molecular Genetics of Cutaneous Lymphomas. Annals of the New York Academy of Sciences, 2001, 941, 39-45.	1.8	21
86	Clinical and Prognostic Significance of Molecular Studies in Cutaneous T-Cell Lymphoma. Current Topics in Pathology Ergebnisse Der Pathologie, 2001, 94, 93-101.	0.2	1
87	Management of Late Stage Cutaneous T-cell lymphoma. Clinical and Experimental Dermatology, 2001, 26, 216-217.	0.6	0
88	Adjuvant therapy in melanoma. Clinical and Experimental Dermatology, 2000, 25, 497-502.	0.6	16
89	Acquired immunobullous disease: a cutaneous manifestation of IgM macroglobulinaemia. British Journal of Dermatology, 1996, 135, 283-286.	1.4	55
90	Phenytoin-induced toxic epidermal necrolysis: a case report. Clinical and Experimental Dermatology, 1996, 21, 116-120.	0.6	10

#	ARTICLE	IF	CITATIONS
91	Pustular psoriasis in pregnancy, and prednisolone. <i>Journal of Dermatological Treatment</i> , 1995, 6, 5-7.	1.1	1
92	Cutaneous necrosis associated with the antiphospholipid syndrome and mycosis fungoides. <i>British Journal of Dermatology</i> , 1994, 130, 92-96.	1.4	44
93	HTLV-1-associated cutaneous disease: a clinicopathological and molecular study of patients from the U. K.. <i>British Journal of Dermatology</i> , 1993, 128, 483-492.	1.4	54
94	Coexistent cutaneous T-cell lymphoma and B-cell chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 1992, 127, 519-523.	1.4	36